Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1268-1271

  Schellens, J H M ^a   Creemers, G J ^a   Beijnen, J H ^b   Rosing, H ^b   De Boer Dennert, M ^a   McDonald, M ^c   Davies, B ^d   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c SmithKline and Beecham   (United Kingdom)

^d SmithKline and Beecham   (United States)

Author keywords

Bioavailability; Topoisomerase I inhibitor; Topotecan

Indexed keywords

ANTINEOPLASTIC ALKALOID; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0029973829     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.243     Document Type: Article

References (19)

1. BEIJNEN JH, SMITH BR, KEIJER WJ, VAN GIJN R, TEN BOKKEL HUININK WW, VLASVELD LT, RODENHUIS S AND UNDERBERG WJ. (1990). High performance liquid chromatographic analysis of the new antitumour drug SK&F 104864 (NSC-609699) in plasma. J. Pharm. Biomed. Anal., 8, 789-794.
2. BLANEY SM, BALIS FM, COLE DE, CRAIG C, REID JM, AMES MM, KRAILO M, REAMAN G, HAMMOND D AND POPLACK DG. (1993). Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53, 1032-1036.
3. BURRIS HA, HANAUSKE AR, JOHNSON RK, MARSHALL MH, KUHN JG, HILSENBECK SG AND VON HOFF DD. (1992). Activity of topotecan, a new topoisomerase I inhibitor, against human tumour colony-forming units in vitro. J. Natl Cancer Inst., 84, 1816-1820.
4. CREEMERS GJ, LUND B AND VERWEIJ J. (1994). Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treatm. Rev., 20, 73-96.
5. GIOVANELLA BC, STEHLIN JS, WALL ME, WANI MC, NICHOLAS AW, LIU LF, SILBER R AND POTMESIL M (1989). DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048.
6. HOCHSTER H, LIEBES L, SPEYER J, SORICH J, TAUBES B, ORATZ R, WERNZ J, CHACHOUA A, RAPHAEL B, VINCI RZ AND BLUM RH. (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12, 553-559.
7. HOUGHTON PJ, CHESHIRE PJ, MYERS L AND HOUGHTON JA. (1992). Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood solid tumours. Cancer Chemother. Pharmacol., 31, 229-239.
8. HSIANG YH AND LIU LF. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48, 1722-1726.
9. JOHNSON RK, MCCABE FL, GALLAGHER G, WOOD J, GALEF J AND HERZBERG RP. (1992). Comparative efficacy of topotecan, irinotecan and of 9-aminocamptothecin in preclinical models. Ann. Oncol., 3 (suppl. 1),105.
10. KINGSBURY WD, BOEHM JC, JAKAS DR, HOLDEN KG, HECHT SM, GALLAGHER G, CARANFA MJ, MCCABE FL, FAUCETTE LF, JOHNSON RK AND HERTZBERG RP. (1991). Synthesis of watersoluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumour activity. J. Med. Chem, 34, 98-107.
11. LOOS WJ, STOTER G, VERWEIJ J AND SCHELLENS JHM. (1996). Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF104864-A) and lactone ring-opened product (hydroxy-acid) in human plasma and urine. J. Chromatogr. Biomed. Appl. (in press).
12. MILLER AA, HARGIS JB, FIELDS S, LILENBAUM RC, ROSNER GL AND SCHILSKY RL. (1993). Phase I study of topotecan and cisplatin in patients with advanced cancer (CALGB 9261). Proc. Am. Soc. Clin. Oncol., 12, 399.
13. ROTHENBERG ML, BURRIS HA, ECKARDT JR, RINALDI DA, WEISS GR, SMITH S, JONES K, JOHNSON RK AND VON HOFF DD. (1993). Phase I/II study of topotecan plus cisplatin in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 12, 156.
14. ROWINSKY EK, GROCHOW LB, HENDRICKS CB, ETTINGER DS, FORASTIERE AA, HUROWITHZ LA, MCGUIRE WP, SARTORIUS SE, LUBEJKO BGM KAUFMANN SH AND DONEHOWER RD. (1992). Phase 1 and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol., 10, 647-656.
15. SCOTT DO, BINDRA DS AND STELLA VJ. (1994). Pharmacokinetics of the lactone and carboxylate forms of 20(S)-camptothecin in anaesthetized rats. Pharm. Res., 10, 1451-1457.
16. SHEINER LB AND BEAL SL. (1985). Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J. Pharmacokinet. Biopharm., 13, 185-201.
17. VERWEIJ J, LUND B, BEIJNEN JH, PLANTING ASTh, DE BOER-DENNERT M, KOIER I, ROSING H AND HANSEN H. (1993). Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4, 673-678.
18. WALL JG, BURRIS H, VON HOFF D, RODRIGUEZ G, KNEUPER-HALL R, SHAFFER D, O'ROURKE T, BROWN T, WEISS G, CLARK G, MCVEA S, BROWN J, JOHNSON RK, FRIEDMAN C, SMITH B, MANN WS AND KUHN J. (1992). A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs, 3, 337-342.
19. YAMAOKA K, NAKAGAWA T AND UNO T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6, 165-175.